Anju Nohria, MD
Dr. Anju Nohria graduated from Harvard Medical School and has a Masters degree in Clinical Epidemiology from Harvard School of Public Health. She completed her residency and chief residency in Internal Medicine from Yale New Haven Hospital, CT. She completed her fellowship in general cardiology with sub-specialty training in heart failure and transplantation at Brigham and Women’s Hospital, MA. She is a faculty member in the advanced heart disease section at Brigham and Women’s Hospital and is the Director of the cardio-oncology program at Brigham and Women’s Hospital and Dana Farber Cancer Institute, MA.
In her role as the Director of the cardio-oncology program, Dr. Nohria has been instrumental in educating patients and physicians about the adverse cardiovascular effects of certain cancer therapies. She has spoken extensively at local and national meetings and has written several review articles and book chapters on this topic. During her tenure at Brigham and Women’s, she has been actively engaged in clinical research in heart failure and vascular medicine. Specifically, she has evaluated various management strategies to improve heart failure outcomes and has been involved in translational research evaluating the contribution of endothelin and the Rho/Rho kinase signal transduction pathway to the pathogenesis of pulmonary hypertension and atherosclerosis. Her recent research efforts are focused in the burgeoning field of cardio-oncology. In particular, she is interested in understanding risk factors that predispose patients to develop cardiotoxicity and is evaluating pharmacologic and non-pharmacologic interventions that might improve functional capacity and cardiovascular outcomes in survivors of cancer therapy.
While members of the Medical Advisory Board are consulted to provide third party expert medical input into Triple-Gene’s product development efforts and clinical trial activities, they do not dictate or direct, nor are they responsible for, any development or clinical activities ultimately undertaken by Triple-Gene.